CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology,
Cytosorbents Corp (NASDAQ: CTSO) shares are trading higher by 15.55% to $1.38 Thursday afternoon after the company announced it received $5 million in non-dilutive debt financing from Bridge Bank and extended a loan agreement.
What's Happening?
PRINCETON, N.J., Dec. 29, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery
CytoSorbents (NASDAQ:CTSO) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement.
Analysts estimate that CytoSorbents will report an earnings per share (EPS) of $-0.16.